Meet The Professors

Nurse and Physician Investigators Discuss Existing and Emerging Treatment Strategies for Patients with Breast Cancer

> Tuesday, July 14, 2020 5:00 PM – 6:00 PM ET

Faculty Virginia Kaklamani, MD, DSc Daniel G Pizana, MSN-FNP, OCN

> Moderator Neil Love, MD



Faculty




Virginia Kaklamani, MD, DSc Professor of Medicine Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment AB Alexander Distinguished Chair in Oncology Associate Director for Clinical Research Leader of the Breast Cancer Program UT Health San Antonio The University of Texas MD Anderson Cancer Center San Antonio, Texas



Daniel G Pizana, MSN-FNP, OCN UT Health San Antonio Mays Cancer Center Breast Oncology Clinic San Antonio, Texas

Dr Love and Faculty Encourage You to Ask Questions



Feel free to submit questions **now before** the program commences and **throughout the program**.

Meet The Professors: Nurse and Physician Investigators Discuss Existing and Emerging Treatment Strategies for Patients with Bladder, Breast and **Prostate Cancer**

Bladder Cancer	Breast Cancer	Prostate Cancer		
Tuesday, July 21, 2020 5:00 PM – 6:00 PM ET	Tuesday, July 14, 2020 5:00 PM – 6:00 PM ET	Thursday, July 16, 2020 5:00 PM – 6:00 PM ET		
Arjun Balar, MD Susan K Roethke, CRNP, MSN, ANP-BC, AOCNP	Virginia Kaklamani, MD, DSc Daniel G Pizana, MSN-FNP, OCN	Matthew R Smith, MD, PhD Kara M Olivier, NP, APRN-BC		
Thursday, July 30, 2020 5:00 PM – 6:00 PM ET	Thursday, July 23, 2020 5:00 PM – 6:00 PM ET	Tuesday, July 28, 2020 5:00 PM – 6:00 PM ET		
Anastassia Daskalova, NP Peter H O'Donnell, MD	Joyce O'Shaughnessy, MD Marissa Marti, APRN, AGNP-C, AOCNP	Robert Dreicer, MD, MS Victoria Sinibaldi, RN, MS, CS, CANP, BC		

All events moderated by Neil Love, MD

ONCOLOGY TODAY WITH DR NEIL LOVE











Make the Meeting Even More Relevant to You

Download the RTP Live app on your smartphone or tablet to access program information, including slides being presented during the program:

www.ResearchToPractice.com/RTPLiveApp



Research To Practice's 2019 San Antonio Breast Cancer Symposia



Meet The Professors

Nurse and Physician Investigators Discuss Existing and Emerging Treatment Strategies for Patients with Breast Cancer

> Tuesday, July 14, 2020 5:00 PM – 6:00 PM ET

Faculty Virginia Kaklamani, MD, DSc Daniel G Pizana, MSN-FNP, OCN

> Moderator Neil Love, MD



Agenda

10 Decisions in Breast Cancer and Where New Agents and Strategies Fit In

Case 1: A 60-year-old woman with ER-positive, HER2-positive breast cancer

- Neoadjuvant, adjuvant treatment of localized disease
- New agents, regimens in metastatic disease

Case 2: A 38-year-old woman with triple-negative breast cancer (TNBC)

- Metastatic TNBC: Atezolizumab/nab paclitaxel, pembrolizumab/chemotherapy
- Neoadjuvant pembrolizumab/chemotherapy in localized TNBC
- Recent FDA approval of sacituzumab govitecan
- Germline and somatic mutation testing
- Indications for and selection of available PARP inhibitors (olaparib, talazoparib)

Case 3: An 80-year-old woman with ER-positive, HER2-negative breast cancer, with a low Recurrence Score

- Chemotherapy versus endocrine therapy for early breast cancer
- Current role of CDK4/6 inhibitors for pre- and postmenopausal women
- Alpelisib/fulvestrant (PIK3CA mutation)

Agenda

10 Decisions in Breast Cancer and Where New Agents and Strategies Fit In

Case 1: A 60-year-old woman with ER-positive, HER2-positive breast cancer

- Neoadjuvant, adjuvant treatment of localized disease
- New agents, regimens in metastatic disease

Case 2: A 38-year-old woman with triple-negative breast cancer (TNBC)

- Metastatic TNBC: Atezolizumab/nab paclitaxel, pembrolizumab/chemotherapy
- Neoadjuvant pembrolizumab/chemotherapy in localized TNBC
- Recent FDA approval of sacituzumab govitecan
- Germline and somatic mutation testing
- Indications for and selection of available PARP inhibitors (olaparib, talazoparib)

Case 3: An 80-year-old woman with ER-positive, HER2-negative breast cancer, with a low Recurrence Score

- Chemotherapy versus endocrine therapy for early breast cancer
- Current role of CDK4/6 inhibitors for pre- and postmenopausal women
- Alpelisib/fulvestrant (PIK3CA mutation)

Case Presentation: A 60-year-old woman with ER-positive, HER2-positive breast cancer

Special Considerations

- Elementary school teacher, very frightened about the pandemic and future risks to herself and her students
- Also concerned that her cancer care may be compromised by the pandemic, resources, etc
- Divorced, no children. Close to family and church
- Palpates a 3 cm breast lump: ER-positive, HER2-positive
 - 1-cm axillary node (biopsy positive)

Decision 1: Surgery or neoadjuvant treatment?

- Paclitaxel/trastuzumab, pertuzumab given (subcutaneously?)
- Surgery: Residual tumor present

Decision 2: Adjuvant treatment?

• TDM-1 given for 16 cycles: grade 1 neuropathy, thrombocytopenia



Case Presentation: A 60-year-old woman with ER-positive, HER2-positive breast cancer (cont)


Decision 3: Post-adjuvant neratinib?

- Neratinib given
- 3 years later while on anastrozole: Bone metastases and 2 liver meta
- Treated with THP and responded but progressed in 18 months
- Responded to TDM-1 but later progressed with extensive bone and liver mets

Decision 4: Third-line treatment

• New roles for trastuzumab deruxtecan and trastuzumab/capecitabine/tucatinib

APHINITY: A Phase III adjuvant study investigating the benefit of pertuzumab when added to trastuzumab + chemotherapy



* Standard anthracycline or non-anthracycline (TCH) regimens were allowed: $3-4 \times FEC$ (or FAC) $\rightarrow 3-4 \times TH$; $4 \times AC$ (or EC) $\rightarrow 4 \times TH$; $6 \times TCH$

- **Primary endpoint:** IDFS (APHINITY definition differs from STEEP definition)
- Secondary endpoint: IDFS with 2nd primary non-breast primary cancers included, DFS, OS, RFI, DRFI, safety, and HRQoL
- Stratification factors: nodal status, HR status, chemotherapy regimen, geographic region, Protocol version (A vs. B)
- Clinical cut off date (CCOD) at the time of primary analysis was 19 Dec 2016, median follow up of 45.4 months


DFS, disease-free survival; DRFI, distant relapse-free interval; HR, hormone receptor; HRQoL, health-related quality of life; IDFS, invasive disease-free survival; OS, overall survival; RFI, relapse-free interval

Courtesy of Virginia Kaklamani, MD DSc

San Antonio Breast Cancer Symposium[®], December 10-14, 2019 Adapted from von Minckwitz et al. N Engl J Med 2017 www.clinicaltrials.gov/ct2/show/NCT01358877

This presentation is the intellectual property of the author/presenter. Contact them at m.piccart@bigagainstbc.org for permission to reprint and/or distribute.

Trastuzumab Emtansine (T-DM1): Mechanisms of Action



KATHERINE Study Design


- cT1-4/N0-3/M0 at presentation (cT1a-b/N0 excluded)
- Centrally confirmed HER2-positive breast cancer
- Neoadjuvant therapy must have consisted of
 - Minimum of 6 cycles of chemotherapy
 - Minimum of 9 weeks of taxane
 - Anthracyclines and alkylating agents allowed
 - All chemotherapy prior to surgery
 - Minimum of 9 weeks of trastuzumab
 - Second HER2-targeted agent allowed
- Residual invasive tumor in breast or axillary nodes
- Randomization within 12 weeks of surgery

Stratification factors:

- Clinical presentation: Inoperable (stage cT4 or cN2–3) vs operable (stages cT1-3N0-1)
- Hormone receptor: ER or PR positive vs ER negative and PR negative/unknown
- Preoperative therapy: Trastuzumab vs trastuzumab plus other HER2-targeted therapy
- Pathological nodal status after neoadjuvant therapy: Positive vs negative/not done

Geyer CE et al. SABCS 2018; Abstract GS1-10.


This presentation is the intellectual property of Charles E. Geyer Jr. Contact him at cegeyer@vcu.edu for permission to reprint and/or distribute.



Radiation and endocrine therapy per protocol and local guidelines

San Antonio Breast Cancer Symposium December 4–8, 2018 Courtesy of Virginia Kaklamani, MD DSc

Invasive Disease-Free Survival




Geyer CE et al. SABCS 2018; Abstract GS1-10.

Courtesy of Virginia Kaklamani, MD DSc

This presentation is the intellectual property of Charles E. Geyer Jr. Contact him at cegeyer@vcu.edu for permission to reprint and/or distribute.

Study Design: ATEMPT Trial




Radiation and endocrine therapy could be initiated after 12 weeks on study therapy

Tolaney SM et al. SABCS 2019; Abstract GS1-05.

This presentation is the intellectual property of the author/presenter. Contact her at stolaney@partners.org for permission to reprint and or distribute

Courtesy of Virginia Kaklamani, MD DSc

ExteNET: Study Design




Primary endpoint:	invasive disease-free survival (iDFS)
Secondary endpoints:	DFS-DCIS, time to distant recurrence, distant DFS, CNS metastases, OS, safety
Other analyses:	biomarkers, health outcome assessment (FACT-B, EQ-5D)
Stratified by:	nodes 0, 1–3 vs. 4+, ER/PR status, concurrent vs. sequential trastuzumab

Follow-up for overall survival is ongoing (estimated: Q3 2019)

CNS=central nervous system; DCIS=ductal carcinoma in situ; ER=estrogen receptor; HER2=human epidermal growth factor receptor 2; IHC=immunohistochemistry; ISH=in situ hybridization; PR=progesterone receptor; OS=overall survival. Martin et al. Lancet Oncol. 2017;18(12):1688-1700. NCT00878709 Courtesy of Virginia Kaklamani, MD DSc


ExteNET: Five-Year Invasive Disease-Free Survival by Patient Population



Martin M et al. *Lancet Oncol* 2017;18(12):1688-700; Martin M et al. ESMO 2017;Abstract 1490.

CONTROL Study Schema

- Prophylactic study to prevent and manage neratinib-associated diarrhea
 - Stage I-IIIc HER2+ disease; prior therapy allowed: endocrine therapy, pertuzumab, and T-DM1




*One cycle=28 days. †Under the original protocol, subjects received loperamide 4 mg initial dose, 2 mg every 4 hours days 1–3, and 2 mg every 6 to 8 hours days 4–56 (n=28) before the "standard" loperamide regimen of 4 mg initial dose, 4 mg TID for 14 days and 4 mg BID days 14–56 was introduced (n=109). All subjects received loperamide as needed (16 mg/day max) after completion of mandated loperamide prophylaxis. Barcenas et al. ASCO 2019 #548.

Courtesy of Virginia Kaklamani, MD DSc

Trastuzumab Deruxtecan (DS-8201) is a Novel ADC Designed to Deliver an Optimal Antitumor Effect

Trastuzumab deruxtecan is an ADC composed of 3 components:

- A humanized anti-HER2 IgG1 mAb with the same amino acid sequence as trastuzumab
- A topoisomerase I inhibitor payload, an exatecan derivative
- A tetrapeptide-based cleavable linker



Payload MOA: topoisomerase I inhibitor High potency of payload High drug to antibody ratio ≈ 8 Payload with short systemic half-life Stable linker-payload Tumor-selective cleavable linker Membrane-permeable payload


The clinical relevance of these features is under investigation. ADC, antibody-drug conjugate; MOA, mechanism of action.

Krop IE et al. SABCS 2019; Abstract GS1-03.

1. Nakada T, et al. Chem Pharm Bull (Tokyo). 2019;67(3):173-185. 2. Ogitani Y, et al. Clin Cancer Res. 2016;22(20):5097-5108. 3. Trail PA, et al. Pharmacol Ther. 2018;181:126-142. 4. Ogitani Y, et al. Cancer Sci. 2016;107(7):1039-1046.

Courtesy of Ian E Krop, MD, PhD


Trastuzumab Deruxtecan's Membrane-permeable Payload Can Attack Neighbouring Cancer Cells (i.e. a bystander effect)



ADCC= antibody-dependent cellular cytotoxicity; HER2=human epidermal growth factor receptor 2; Topo-1=topoisomerase I.

1. Ogitani Y et al. Cancer Sci. 2016;107:1039–1046 . 2. Ogitani Y et al. Clin Cancer Res. 2016;22:5097–5108. Courtesy of Ian E Krop, MD, PhD

Trastuzumab Deruxtecan in HER2-Positive mBC Previously Treated with T-DM1: Best Tumor Size Response



Krop IE et al. SABCS 2019; Abstract GS1-03.

Courtesy of Virginia Kaklamani, MD DSc

This presentation is the intellectual property of the author/presenter. Contact them at <u>ikrop@partners.org</u> for permission to reprint and/or distribute.

DESTINY-Breast01: Adverse Events of Special Interest: Interstitial Lung Disease

	Patients who received T-DXd 5.4 mg/kg (N=184)							
Preferred Term, n (%)	Grade 1	Grade 2	Grade 3	Grade 4	Grade 5	Any Grade/ Total		
Interstitial lung disease	5 (2.7)	15 (8.2)	1 (0.5)	0	4 (2.2)	25 (13.6)		

Drug related; ILD was determined by the Independent ILD Adjudication Committee based on 44 preferred terms.

Among the 25 total events:

- Median time to investigator-reported onset was 193 days (range, 42-535 days)
- 17 of 20 patients with grade \geq 2 ILD received corticosteroids
- 7 patients recovered, 2 were recovering, 12 were either outcome unknown or not followed until resolution, and 4 died
- Of the 4 fatal cases, onset was from 63-148 days, 3 received steroids as part of treatment, and death occurred 9-60 days after diagnosis

Recommendations: Monitor for symptoms. Hold T-DXd and start steroids as soon as ILD is suspected


ILD, interstitial lung disease.

HER2CLIMB Trial Design

Key Eligibility Criteria

- HER2+ metastatic breast cancer
- Prior treatment with trastuzumab, pertuzumab, and T-DM1
- ECOG performance status 0 or 1
- Brain MRI at baseline
 - Previously treated stable brain metastases
 - Untreated brain metastases not needing immediate local therapy
 - Previously treated progressing brain metastases not needing immediate local therapy
 - No evidence of brain metastases


*Stratification factors: presence of brain metastases (yes/no), ECOG status (0 or 1), and region (US or Canada or rest of world) San Antonio Breast Cancer Symposium[®], December 10-14, 2019



https://clinicaltrials.gov/ct2/show/NCT02614794 Murthy R et al. SABCS 2019;Abstract GS1-01. Courtesy of Virginia Kaklamani, MD DSc

This presentation is the intellectual property of the author/presenter. Contact them at <u>rmurthy1@mdanderson.org</u> for permission to reprint and/or distribute.

Most Common Adverse Events (≥20% in the Tucatinib Arm)



PPE: palmar-plantar erythrodysesthesia, AST: aspartate transaminase, ALT: alanine transaminase

Murthy R et al. SABCS 2019; Abstract GS1-01.

Courtesy of Virginia Kaklamani, MD DSc

This presentation is the intellectual property of the author/presenter. Contact them at <u>rmurthy1@mdanderson.org</u> for permission to reprint and/or distribute.

Agenda

10 Decisions in Breast Cancer and Where New Agents and Strategies Fit In

Case 1: A 60-year-old woman with ER-positive, HER2-positive breast cancer

- Neoadjuvant, adjuvant treatment of localized disease
- New agents, regimens in metastatic disease

Case 2: A 38-year-old woman with triple-negative breast cancer (TNBC)

- Metastatic TNBC: Atezolizumab/nab paclitaxel, pembrolizumab/chemotherapy
- Neoadjuvant pembrolizumab/chemotherapy in localized TNBC
- Recent FDA approval of sacituzumab govitecan
- Germline and somatic mutation testing
- Indications for and selection of available PARP inhibitors (olaparib, talazoparib)

Case 3: An 80-year-old woman with ER-positive, HER2-negative breast cancer, with a low Recurrence Score

- Chemotherapy versus endocrine therapy for early breast cancer
- Current role of CDK4/6 inhibitors for pre- and postmenopausal women
- Alpelisib/fulvestrant (PIK3CA mutation)

Case Presentation: A 38-year-old woman with TNBC

Special considerations

- Speaks only Spanish (clinic staff are generally not bilingual)
- Day laborer with husband and 2 children, 11 and 14 years old.
- Drives 3 hours to the clinic
- Believes in nontraditional medicine
- Self palpates a 3-cm mass
- Biopsy: TNBC
- 2 small axillary nodes seen on ultrasound; biopsy positive

Decision 1: Neoadjuvant treatment or primary surgery?

• Anthracycline/taxane chemotherapy: Good response but residual disease at surgery

Decision 2: Post-neoadjuvant treatment?

• Capecitabine is given, but 9 months later: Bone and lung mets



Case Presentation: A 38-year-old woman TNBC (cont)

Decision 3: First-line mets. Role of genomic evaluation/PD-L1 levels?

- Atezolizumab + *nab*-paclitaxel given, followed by a PARP inhibitor maintenance
 - Patient doing well on olaparib maintenance therapy
- Genetic counseling and testing is offered to the family

IMpassion130 Study Design


Key IMpassion130 eligibility criteria^a:

- Metastatic or inoperable locally advanced TNBC
 - Histologically documented^b
- No prior therapy for advanced TNBC
 - Prior chemo in the curative setting, including taxanes, allowed if TFI ≥ 12 mo

• ECOG PS 0-1

Stratification factors:

- Prior taxane use (yes vs no)
- Liver metastases (yes vs no)
- PD-L1 status on IC (positive [≥ 1%] vs negative [< 1%])^c




- Co-primary endpoints were PFS and OS in the ITT and PD-L1+ populations^d
 - Key secondary efficacy endpoints (ORR and DOR) and safety were also evaluated

IC, tumour-infiltrating immune cell; TFI, treatment-free interval. ^a ClinicalTrials.gov: NCT02425891. ^b Locally evaluated per ASCO–College of American Pathologists (CAP) guidelines. ^c Centrally evaluated per VENTANA SP142 IHC assay (double blinded for PD-L1 status). ^d Radiological endpoints were investigator assessed (per RECIST v1.1).

Courtesy of Joyce O'Shaughnessy, MD


KEYNOTE-355: A Phase III Study of Chemotherapy +/-Pembrolizumab



Primary endpoints: Progression-free and overall survival

- In Part 1, individual chemo regimens combined with pembrolizumab were evaluated.
- In Part 2, participants receive 1 of 3 chemo regimens: *nab* paclitaxel, paclitaxel or gemcitabine/carboplatin.

Sacituzumab Govitecan Mechanism of Action – Trop-2-Directed Antibody-Drug Conjugate



1. Monoclonal antibody (hRS7)

 Binds to Trop-2, a cell surface antigen highly expressed by many cancers, including TNBC

2. Hydrolyzable linker (CL2A)

- Helps to ensure that an active concentration of SN-38 is maintained in the tumor
- Hydrolysis of the linker releases the cytotoxic payload intracellularly and in the tumor microenvironment to kill cells

3. Cytotoxic payload (SN-38)

 Topoisomerase I inhibitor that blocks DNA replication, leading to double-stranded DNA breaks via multiple mechanisms

Favorable Therapeutic Index

- SG has a high DAR (7.6:1 or 7-8 molecules of SN-38 per antibody), enhancing drug delivery to tumor
 - Other ADCs have 3 or 4 to 1 ratios^{2,3}
- Moderate drug potency mitigates toxicity, while increased intratumoral drug release enhances efficacy
 - Other ADCs have highly toxic payloads

FDA Grants Accelerated Approval to Sacituzumab Govitecan for Metastatic TNBC

Press Release – April 22, 2020


"The Food and Drug Administration granted accelerated approval to sacituzumab govitecan-hziy for adult patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease.

Efficacy was demonstrated in IMMU-132-01 (NCT 01631552), a multicenter, single-arm trial enrolling 108 patients with metastatic triple negative breast cancer (mTNBC) who received at least two prior treatments for metastatic disease. Patients received sacituzumab govitecan-hziy 10 mg/kg intravenously on days 1 and 8 every 21 days. Tumor imaging was obtained every 8 weeks, and patients were treated until disease progression or intolerance to therapy.

The primary efficacy outcome measures were investigator assessed overall response rate (ORR) using RECIST 1.1 and response duration. The ORR was 33.3%. The median response duration was 7.7 months."


https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-sacituzumab-govitecan-hziy-metastatic-triple-negative-breast-cancer

Mechanism of Cell Death from Synthetic Lethality Induced by PARP Inhibition




Courtesy of Jenny C Chang, MD

Common Side Effects of PARP Inhibitors Olaparib and Talazoparib



Litton JK et al. *N Engl J Med* 2018;379(8):753-63. Robson M et al. *N Engl J Med* 2017;377(6):523-33.


Phase III trials of PARP inhibitors in gBRCA HER2-negative metastatic breast cancer patients



Robson et al. *N Engl J Med* 2017; 377:523-533;
Litton J et al. *N Engl J Med* 2018; 379:753-763

Phase III trials of PARP inhibitors in gBRCA HER2-negative metastatic breast cancer patients

Olaparib and talazoparib both improve PFS in gBRCA mBC patients vs chemotherapy of physician's choice



OlympiAD: Olaparib PFS^{1,2}

EMBRACA: Talazoparib PFS³

1. Robson M, et al. N Engl J Med. 2017;377:523-533; 2. Olaparib 150mg Film-Coated Tablets, SmPC. 2019; 3. Litton JK, et al. N Engl J Med. 2018;379:753-763 (supplementary appendix)

Courtesy of Joyce O'Shaughnessy, MD

Agenda

10 Decisions in Breast Cancer and Where New Agents and Strategies Fit In

Case 1: A 60-year-old woman with ER-positive, HER2-positive breast cancer

- Neoadjuvant, adjuvant treatment of localized disease
- New agents, regimens in metastatic disease

Case 2: A 38-year-old woman with triple-negative breast cancer (TNBC)

- Metastatic TNBC: Atezolizumab/nab paclitaxel, pembrolizumab/chemotherapy
- Neoadjuvant pembrolizumab/chemotherapy in localized TNBC
- Recent FDA approval of sacituzumab govitecan
- Germline and somatic mutation testing
- Indications for and selection of available PARP inhibitors (olaparib, talazoparib)

Case 3: An 80-year-old woman with ER-positive, HER2-negative breast cancer, with a low Recurrence Score

- Chemotherapy versus endocrine therapy for early breast cancer
- Current role of CDK4/6 inhibitors for pre- and postmenopausal women
- Alpelisib/fulvestrant (PIK3CA mutation)

Case Presentation: An 80-year-old woman with ER-positive, HER2-negative breast cancer, with a low Recurrence Score

Special considerations

- Husband died of lung cancer 4 years ago
- Currently, raising 2 grandchildren alone (8 and 12 years old)
- Overweight, with type 2 diabetes on insulin, antihypertensive and 3 other agents
- Disorganized about taking medications

Decision 1: Chemotherapy or not?

- Lumpectomy followed by anastrozole
- While on anastrozole, she is found to have moderately symptomatic bone mets
 - Focal radiation therapy



Case Presentation: An 80-year-old woman with ER-positive, HER2-negative breast cancer, with a low Recurrence Score (cont)


Decision 2: Chemotherapy or endocrine therapy (which endocrine therapy)?

- Treated with fulvestrant and a CDK4/6 inhibitor
- Patient did well but disease progressed after 2 years, with new liver mets
- Patient was stable clinically
- PI3K mutation detected in the tumor

Decision 3: Chemotherapy or endocrine therapy (which endocrine therapy)?

• Alpelisib, everolimus combinations

CDK4/6 Regulates Cell Cycle Progression



M, mitosis; Rb, retinoblastoma. Adapted from Finn et al, 2016.


Common Side Effects and Dosing of CDK4/6 Inhibitors

Dosing	Palbociclib 125 mg qd 3 wk on, 1 wk off		Abema 200 m continu	g BID	Ribociclib 600 mg qd 3 wk on, 1 wk off	
Common adverse events	All grades	Grade 3/4	All grades	Grade 3/4	All grades	Grade 3/4
Neutropenia	95%	54%	88%	27%	46%	29%
Thrombocytopenia	76%	19%	42%	2%	37%	10%
Diarrhea	16%	0	90%	20%	22%	3%
Nausea	23%	0	65%	5%	46%	2%
Vomiting	5%	0	35%	2%	25%	0

Barroso-Sousa R et al. Breast Care 2016;11:167-73.

SOLAR-1: Alpelisib Improved PFS in the *PIK3CA*-mutant Cohort^{1,a}

Fulvestrant + Alpelisib or Placebo in ER+ HER2- mBC Patients Resistant to Al Therapy



Data cut-off: Jun 12, 2018	ALP + FUL (n = 169)	PBO + FUL (n = 172)		
Number of PFS events, n (%)	103 (60.9)	129 (75.0)		
Progression	99 (58.6)	120 (69.8)		
Death	4 (2.4)	9 (5.2)		
Censored	66 (39.1)	43 (25.0)		
Median PFS (95% CI)	11.0 (7.5-14.5)	5.7 (3.7-7.4)		
HR (95% CI)	0.65 (0.50-0.85)			
One-sided <i>P</i> value	0.00065			

Number of subjects still at risk

Alpelisib + Fulv 169 158 145 141 12	23 113 97	95 85 82	75 71 62	2 54 50 43	3 39 32 30 27	17 16 14	554	3 3 1	1 1 0
Placebo + Fulv 172 167 120 111 8	9 88 80	77 67 66	58 54 48	41 37 29	9 29 21 20 19	14 13 9	3 3 2	2 2 0	0 0 0

CI, confidence interval; HR, hazard ratio; PFS, progression-free survival.

At final PFS analysis, superiority was declared if one-sided, stratified log-rank test P value was ≤ 0.0199 (Haybittle–Peto boundary).

^a Mutation status determined from tissue biopsy.

1. Andre F, et al. ESMO 2018. Abstract LBA3 [oral].

Meet The Professors

Nurse and Physician Investigators Discuss Existing and Emerging Treatment Strategies for Patients with Prostate Cancer

> Thursday, July 16, 2020 5:00 PM – 6:00 PM ET

Faculty Matthew R Smith, MD, PhD and Kara M Olivier, NP, APRN-BC

> Moderator Neil Love, MD



Thank you for joining us!

CNE (NCPD) credit information will be emailed to each participant tomorrow morning.